Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urology and Nephrology 2022 October;74(5) > Minerva Urology and Nephrology 2022 October;74(5):646-7

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

LETTERS TO THE EDITOR   

Minerva Urology and Nephrology 2022 October;74(5):646-7

DOI: 10.23736/S2724-6051.22.04924-2

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Do we have enough evidence for approval of nadofaragene firadenovec?

Murat AKAND 1, 2 , Frank VAN DER AA 1, Steven JONIAU 1

1 Department of Urology, University Hospitals Leuven, Leuven, Belgium; 2 Organ Systems, KU Leuven, Leuven, Belgium



top of page